# Regulatory Framework Reference

## Governing Documents for Cell Therapy Development

### Clinical Trial Conduct
| Document | ID | Scope |
|----------|----|-------|
| Good Clinical Practice | ICH E6(R3) | Comprehensive GCP standard for design, conduct, monitoring, auditing of clinical trials |
| General Considerations for Clinical Studies | ICH E8(R1) | Quality-by-design approach to clinical study planning |
| Statistical Principles | ICH E9(R1) | Estimands and statistical methodology for confirmatory trials |
| Clinical Investigation of Medicinal Products in Geriatric Population | ICH E7 | Age-specific considerations |
| Multiregional Clinical Trials | ICH E17 | Planning and design for global trials |
| Investigational New Drug Applications | 21 CFR 312 | US IND requirements, safety reporting, sponsor obligations |
| Protection of Human Subjects | 21 CFR 50 | Informed consent, IRB review requirements |
| Institutional Review Boards | 21 CFR 56 | IRB composition, functions, operations |

### Pharmacovigilance & Safety
| Document | ID | Scope |
|----------|----|-------|
| Clinical Safety Data Management: Definitions and Standards | ICH E2A | Defines adverse events, serious AEs, expected/unexpected classification |
| Clinical Safety Data Management: Data Elements for Transmission | ICH E2B(R3) | ICSR electronic transmission format (E2B XML) |
| Periodic Safety Update Reports | ICH E2C(R2) | PSUR/PBRER content, format, and submission requirements |
| Post-Approval Safety Data Management | ICH E2D | Expedited and periodic reporting obligations post-approval |
| Pharmacovigilance Planning | ICH E2E | Risk management planning, pharmacovigilance plan structure |
| Development Safety Update Report | ICH E2F | DSUR content and format for ongoing clinical trials |
| IND Safety Reporting | 21 CFR 312.32 | US expedited safety reporting for IND studies (7/15-day rules) |
| Post-Marketing Safety Reporting | 21 CFR 314.80 | US post-marketing AE reporting requirements |
| CIOMS I-VI Working Group Reports | CIOMS I-VI | International consensus on safety reporting, signal detection, benefit-risk |
| MedDRA | ICH M1 | Medical Dictionary for Regulatory Activities — standardized AE terminology |

### Cell Therapy / Gene Therapy Specific
| Document | ID | Scope |
|----------|----|-------|
| Human Cells, Tissues, and Cellular and Tissue-Based Products | 21 CFR 1271 | Registration, listing, donor eligibility, GTP |
| Biological Products: General | 21 CFR 600-680 | BLA requirements, lot release, labeling for biologics |
| PHS Act Section 351 | 42 USC 262 | Federal authority for regulation of biological products |
| FDA Guidance: Chemistry, Manufacturing, and Control for Cell Therapy | CBER | CMC requirements specific to cell and gene therapy products |
| FDA Guidance: Long-Term Follow-Up After Administration of Cell/Gene Therapy | CBER | 15-year follow-up recommendation for gene therapy, 5-year for cell therapy |
| FDA Guidance: Considerations for Design of Early-Phase Clinical Trials of CGT Products | CBER | Dose escalation, patient selection, safety monitoring for FIH trials |
| FDA Guidance: Testing of Retroviral Vector-Based Gene Therapy Products | CBER | RCL testing, vector characterization requirements |
| FDA Guidance: Eligibility Determination for Donors of HCT/Ps | CBER | Donor screening and testing requirements |
| EMA ATMP Classification | EU Reg 1394/2007 | European classification and requirements for Advanced Therapy Medicinal Products |
| REMS (Risk Evaluation and Mitigation Strategy) | 21 CFR 314 Subpart H | Post-market risk management programs (note: CAR-T REMS eliminated July 2025) |

### Ethics
| Document | ID | Scope |
|----------|----|-------|
| Declaration of Helsinki | WMA 2013 | Ethical principles for medical research involving human subjects |
| Belmont Report | 1979 | Respect for persons, beneficence, justice — foundational ethical framework |
| Common Rule | 45 CFR 46 | US federal regulations for protection of human subjects in research |
| Nuremberg Code | 1947 | Ten principles for permissible medical experiments |
| ICH E11(R1) | ICH | Ethical considerations for pediatric clinical studies |

### Quality / GxP
| Document | ID | Scope |
|----------|----|-------|
| Good Manufacturing Practice (Drugs) | 21 CFR 210/211 | cGMP for drug products |
| Good Manufacturing Practice (Biologics) | 21 CFR 600 | GMP specific to biological products |
| Good Tissue Practice | 21 CFR 1271 Subpart D | GTP for cell and tissue-based products |
| Good Laboratory Practice | 21 CFR 58 | GLP for nonclinical laboratory studies |
| Electronic Records; Electronic Signatures | 21 CFR Part 11 | Requirements for electronic data, audit trails, system validation |
| Quality Risk Management | ICH Q9(R1) | Risk assessment, risk control, risk review for pharmaceutical quality |
| Pharmaceutical Quality System | ICH Q10 | Lifecycle approach to quality management |
| Pharmaceutical Development | ICH Q8(R2) | Quality-by-design, design space, control strategy |
| Good Distribution Practice | ICH Q10 / EU GDP | Chain of custody, cold chain, product integrity during distribution |
| Data Integrity | FDA/EMA/MHRA | ALCOA+ principles for data integrity in GxP environments |

### Regulatory Submissions
| Document | ID | Scope |
|----------|----|-------|
| Common Technical Document | ICH M4 | CTD format for regulatory submissions (Modules 1-5) |
| Electronic Common Technical Document | ICH M8 | eCTD electronic submission format and validation |
| IND Content and Format | 21 CFR 312.23 | Required content for US IND applications |
| BLA Content and Format | 21 CFR 601 | Requirements for Biologics License Application |
| Breakthrough Therapy Designation | FDA | Expedited program for serious conditions with preliminary clinical evidence |
| Regenerative Medicine Advanced Therapy (RMAT) | FDA | Expedited designation specific to regenerative medicine products |
| PRIME (Priority Medicines) | EMA | European accelerated assessment pathway |

### Biostatistics
| Document | ID | Scope |
|----------|----|-------|
| Statistical Principles for Clinical Trials | ICH E9 | Fundamental statistical principles for confirmatory trials |
| Estimands and Sensitivity Analysis | ICH E9(R1) | Addendum defining estimand framework |
| Dose-Response Studies | ICH E4 | Design and analysis of dose-response information |
| Adaptive Designs | FDA Guidance | Adaptive trial design with pre-specified modifications |
| Bayesian Statistics in Medical Device Trials | FDA Guidance | Applicable principles for Bayesian approaches |
| Missing Data in Confirmatory Trials | NRC/FDA | Approaches to handling missing data |

---

## Critical Path: IND to BLA for Cell Therapy

| Milestone | Owner | Key Regulations | Timeline |
|-----------|-------|----------------|----------|
| 1. Target/Product Selection | CMO + Head R&D | — | Pre-IND |
| 2. Nonclinical Studies (Tox, Biodistribution) | Head CMC | 21 CFR 58 (GLP) | 12-18 months |
| 3. CMC Development (Manufacturing, Release Testing) | Head CMC | 21 CFR 1271, CBER guidance | 12-24 months |
| 4. IND Preparation & Filing | VP Regulatory | 21 CFR 312.23, ICH M4 | 2-3 months |
| 5. FDA Pre-IND Meeting | VP Regulatory + CMO | FDA Meeting guidance | 1-2 months |
| 6. IND Submission & 30-Day Safety Review | VP Regulatory | 21 CFR 312 | 30 days |
| 7. Phase I (First-in-Human, Dose Escalation) | VP Clinical Ops | ICH E6, CBER early-phase guidance | 12-24 months |
| 8. DSUR Preparation (Annual) | Head PV | ICH E2F | Annual during IND |
| 9. Phase II (Dose Optimization, Efficacy Signal) | VP Clinical Ops + Head Biostats | ICH E8, E9 | 18-36 months |
| 10. End-of-Phase-2 Meeting with FDA | VP Regulatory + CMO | FDA Meeting guidance | 2-3 months |
| 11. Phase III (Pivotal/Confirmatory) | VP Clinical Ops | ICH E9(R1), adaptive design | 24-48 months |
| 12. BLA Preparation | VP Regulatory | 21 CFR 601, ICH M4 eCTD | 6-12 months |
| 13. Pre-BLA Meeting | VP Regulatory + CMO | FDA Meeting guidance | 2-3 months |
| 14. BLA Submission | VP Regulatory | 21 CFR 601, eCTD | — |
| 15. FDA Review (Priority Review: 6 mo, Standard: 10 mo) | VP Regulatory | PDUFA | 6-10 months |
| 16. Advisory Committee Meeting | CMO + VP Regulatory | FDA AdComm guidance | If requested |
| 17. RMAT/Breakthrough Designation (if applicable) | VP Regulatory | FDA RMAT guidance | Parallel track |
| 18. Approval & Post-Market Commitments | All | REMS, PMR/PMC, long-term follow-up | Ongoing |
